Genprex (NASDAQ:GNPX) Stock Price Down 3.9%

Genprex, Inc. (NASDAQ:GNPX) shares traded down 3.9% on Wednesday . The company traded as low as $1.93 and last traded at $1.96. 35,531 shares changed hands during trading, a decline of 62% from the average session volume of 94,474 shares. The stock had previously closed at $2.04.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Genprex in a report on Wednesday, May 15th.

Genprex Trading Down 3.9 %

The company has a fifty day moving average of $2.36 and a 200 day moving average of $4.72.

Genprex (NASDAQ:GNPX) last announced its earnings results on Wednesday, May 15th. The company reported ($3.69) EPS for the quarter, missing the consensus estimate of ($2.54) by ($1.15). On average, analysts expect that Genprex, Inc. will post -5.7 EPS for the current year.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.